Novartis Medical’s Post

Coming out of #ASCO24, we’re excited to further our work in supporting patients living with difficult-to-treat cancers such as gastroesophageal adenocarcinoma (GEA). HER2 has emerged as a compelling target for patients whose cancer displays HER2-positivity, including some GEA patients, which is why testing for HER2-expression in patients diagnosed with GEA is critical to determining the appropriate treatment option. Hear from Elaina Gartner, Vice President Medical, Late-Stage Development, Oncology Clinical Development, as she details more about the role of #HER2 in GEA. https://bit.ly/3Rier2V

Generic Name: Teclistamab-cqyv Drug Type: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager How the Drug is Given: Injection, for subcutaneous use

Appreciate this interview with oncology leaders on Drug Shortages in the US - Kirollos Hanna, PharmD, BCPS, BCOP, FACCC American Cancer Society #AmericanCancerSociety #Cancer #DrugShortage #Healthcare #OncoDaily #Oncology #OncologyLeaders

📈 Webinar Highlight: Transforming Oncology Care with Real-World Evidence Insights As oncology treatments become increasingly complex, healthcare professionals and the industry face significant data challenges. How can Real-World Evidence (RWE) be leveraged to address these issues? 📘 Join our session with Michael Pröschel of iOMEDICO and our in-house expert Christoph Mayer of Temedica to explore the dynamic role of real-world data types and sources in simplifying complex cancer treatment data. Learn how RWE can be utilized to better understand patient populations and optimize future treatments! 📌 November 29, 17:00 CET (Webinar in German) 🔗 Register here: https://lnkd.in/e835hHXg #oncologyeducation #realworldevidence #healthcaretrends

✍️ Must Read this amazing article about the 7 Ways Oncology Pharmacists Impact #Cancer Care 1. Drug interactions 2. Comorbid conditions 3. Baseline organ dysfunction 4. Tolerability of previous cycles 5. Pharmacogenomics 6. Patient weight 7. Under/ over-dosing implications https://lnkd.in/dVjPWTpK

Launching #MyelomaAwarenessMonth with a MAJOR WIN for myeloma patients! 🌟 The U.S. FDA recently approved a myeloma treatment that may reduce treatment costs, frequency, and side effects. This signifies a shift toward more tolerable treatments for blood cancer patients. ❤️ Discover the details and see how LLS is spearheading efforts to make blood cancer treatments easier for patients 👉 https://bit.ly/48BkJ3q

✍️ Must Read this amazing article about the 7 Ways Oncology Pharmacists Impact #Cancer Care 1. Drug interactions 2. Comorbid conditions 3. Baseline organ dysfunction 4. Tolerability of previous cycles 5. Pharmacogenomics 6. Patient weight 7. Under/ over-dosing implications https://lnkd.in/dZYWHPqu

From new approvals and shortages to precision medication, change and innovation seem to be the only constants in oncology. See more on the trends, breakthroughs and challenges shaping cancer care. ⬇️ Download the report: http://spr.ly/6047evuBP

#DidYouKnow – there are #ClinicalTrials available for every step of a patient’s cancer journey and all stages of melanoma. You can join a clinical trial before or after trying other FDA-approved treatments. In partnership with Bristol Myers Squibb, we created this clinical trial infographic to better inform patients, caregivers and our entire #melanoma community about their treatment options - https://buff.ly/43MfoFT

Patients and society won’t reap the benefits of precision oncology unless we democratize this data, that is, make it available to the patients who need it when they need it. With a few practical improvements to current care pathways, we could achieve this, meet the need for urgency, and empower patients. Stacy Hurt 🌻, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/gBkJMKt2 #PrecisionOncology #NovelInsights #PatientsFirst #PatientData #ASCO24